In a report released today, Geoff Porges from Leerink Partners maintained a Buy rating on FibroGen (NASDAQ: FGEN), with a price target of $84. The company’s shares closed on Friday at $49.79.
According to TipRanks.com, Porges is a 3-star analyst with an average return of 3.9% and a 43.8% success rate. Porges covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Principia Biopharma Inc, and Restorbio Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for FibroGen with a $76.33 average price target, which is a 53.3% upside from current levels. In a report issued on October 1, Mizuho Securities also maintained a Buy rating on the stock with a $74 price target.
.
See today’s analyst top recommended stocks >>
Based on FibroGen’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.42 million. In comparison, last year the company had a GAAP net loss of $37.74 million.
Based on the recent corporate insider activity of 126 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Toshinari Tamura, a Director at FGEN sold 12,000 shares for a total of $727,800.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
